<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39336949</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Subsequent Vaccination against SARS-CoV-2 after Vaccine-Induced Immune Thrombotic Thrombocytopenia.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5462</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13185462</ELocationID><Abstract><AbstractText><b>Background:</b> Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but severe complication following vaccination with adenovirus vector-based COVID-19 vaccines. Antibodies directed against platelet factor 4 (PF4) are thought to be responsible for platelet activation and subsequent thromboembolic events in these patients. Since a single vaccination does not lead to sufficient immunization, subsequent vaccinations against COVID-19 have been recommended. However, concerns exist regarding the possible development of a new thromboembolic episode after subsequent vaccinations in VITT patients. <b>Methods:</b> We prospectively analyzed follow-up data from four VITT patients (three women and one man; median age, 44 years [range, 22 to 62 years]) who subsequently received additional COVID-19 vaccines. Platelet counts, anti-PF4/heparin antibody level measurements, and a functional platelet activation assay were performed at each follow-up visit. Additionally, we conducted a literature review and summarized similar reports on the outcome of subsequent vaccinations in patients with VITT. <b>Results:</b> The patients had developed thrombocytopenia and thrombosis 4 to 17 days after the first vaccination with ChAdOx1 nCoV-19. The optical densities (ODs) of anti-PF4/heparin antibodies decreased with time, and three out of four patients tested negative within 4 months. One patient remained positive even after 10 months post first vaccination. All four patients received an mRNA-based vaccine as a second vaccination against SARS-CoV-2. No significant drop in platelet count or new thromboembolic complications were observed during follow-up. We identified seven publications reporting subsequent COVID-19 vaccination in VITT patients. None of the patients developed thrombocytopenia or thrombosis after the subsequent vaccination. <b>Conclusion:</b> Subsequent vaccination with an mRNA vaccine appears to be safe in VITT patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uzun</LastName><ForeName>Günalp</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8717-6230</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Transfusion Medicine Tuebingen, 72076 Tuebingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, 72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringelmann</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, 72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammer</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0000-8005-2916</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Transfusion Medicine Tuebingen, 72076 Tuebingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, 72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zlamal</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Clinical Transfusion Medicine Tuebingen, 72076 Tuebingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, 72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luz</LastName><ForeName>Beate</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Transfusion Medicine, Klinikum Stuttgart, 70174 Stuttgart, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Marc E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-7683-6918</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Klinikum Stuttgart, 70174 Stuttgart, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henkes</LastName><ForeName>Hans</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-6534-036X</Identifier><AffiliationInfo><Affiliation>Department of Neuroradiology, Klinikum Stuttgart, 70174 Stuttgart, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakchoul</LastName><ForeName>Tamam</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6797-6812</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Transfusion Medicine Tuebingen, 72076 Tuebingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, 72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Althaus</LastName><ForeName>Karina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for Clinical Transfusion Medicine Tuebingen, 72076 Tuebingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, 72076 Tuebingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TSG Study</GrantID><Agency>Herzstiftung</Agency><Country /></Grant><Grant><GrantID>BA515874</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">platelet factor 4</Keyword><Keyword MajorTopicYN="N">thrombocytopenia</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList><CoiStatement>Tamam Bakchoul has received research funding from CoaChrom Diagnostica GmbH, DFG, Robert Bosch GmbH, Stiftung Transfusionsmedizin und Immunhämatologie e.V.: Ergomed, DRK Blutspendedienst, Deutsche Herzstiftung, Ministerium fuer Wissenschaft, Forschung und Kunst Baden-Wuerttemberg, has received lecture honoraria from Aspen Germany GmbH, Bayer Vital GmbH, Bristol-Myers Squibb GmbH &amp; Co., Doctrina Med AG, Meet The Experts Academy UG, Schoechl medical education GmbH, Stago GmbH, Mitsubishi Tanabe Pharma GmbH, Novo Nordisk Pharma GmbH, Leo Pharma GmbH, Swedish Orphan Biovitrum GmbH, has provided consulting services to Terumo, and has provided expert witness testimony relating to heparin-induced thrombocytopenia (HIT) and non-HIT thrombocytopenic and coagulopathic disorders. All of these are outside the current work. Karina Althaus received honoraria for lectures from CSL Behring, Sobi, Meet the Expert, Expanda, and Werfen, paid to the Medical University Hospital of Tübingen. She also received research grants from Octapharma and Bayer, also allocated to the Medical University Hospital of Tübingen. All outside of this work. Other authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39336949</ArticleId><ArticleId IdType="pmc">PMC11431967</ArticleId><ArticleId IdType="doi">10.3390/jcm13185462</ArticleId><ArticleId IdType="pii">jcm13185462</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine: Action Advances Fight Against COVID-19, Follows Comprehensive Evaluation of Available Safety, Effectiveness and Manufacturing Quality Information by FDA Career Scientists, Input from External Experts.  [(accessed on 26 August 2024)]; Available online:  https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine.</Citation></Reference><Reference><Citation>EMA Recommends COVID-19 Vaccine AstraZeneca for Authorisation in the EU. 2021 29.01.2021.  [(accessed on 26 August 2024)].  Available online:  https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu.</Citation></Reference><Reference><Citation>Bhuyan P., Medin J., da Silva H.G., Yadavalli M., Shankar N.K., Mullerova H., Arnold M., Nord M. Very rare thrombosis with thrombocytopenia after second AZD1222 dose: A global safety database analysis. Lancet. 2021;398:577–578. doi: 10.1016/S0140-6736(21)01693-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01693-7</ArticleId><ArticleId IdType="pmc">PMC9753120</ArticleId><ArticleId IdType="pubmed">34329583</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Aid M., Stephenson K.E., Collier A.Y., Nkolola J.P., Michael J.V., McKenzie S.E., Barouch D.H. Activation of coagulation and proinflammatory pathways in thrombosis with thrombocytopenia syndrome and following COVID-19 vaccination. Nat. Commun. 2023;14:6703. doi: 10.1038/s41467-023-42559-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-42559-x</ArticleId><ArticleId IdType="pmc">PMC10593859</ArticleId><ArticleId IdType="pubmed">37872311</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A., Thiele T., Warkentin T.E., Weisser K., Kyrle P.A., Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N. Engl. J. Med. 2021;384:2092–2101. doi: 10.1056/NEJMoa2104840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104840</ArticleId><ArticleId IdType="pmc">PMC8095372</ArticleId><ArticleId IdType="pubmed">33835769</ArticleId></ArticleIdList></Reference><Reference><Citation>Althaus K., Möller P., Uzun G., Singh A., Beck A., Bettag M., Bösmüller H., Guthoff M., Dorn F., Petzold G.C., et al. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica. 2021;106:2170–2179. doi: 10.3324/haematol.2021.279000.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2021.279000</ArticleId><ArticleId IdType="pmc">PMC8327736</ArticleId><ArticleId IdType="pubmed">34011137</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz N.H., Sørvoll I.H., Michelsen A.E., Munthe L.A., Lund-Johansen F., Ahlen M.T., Wiedmann M., Aamodt A.H., Skattør T.H., Tjønnfjord G.E., et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med. 2021;384:2124–2130. doi: 10.1056/NEJMoa2104882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104882</ArticleId><ArticleId IdType="pmc">PMC8112568</ArticleId><ArticleId IdType="pubmed">33835768</ArticleId></ArticleIdList></Reference><Reference><Citation>Pai M. Epidemiology of VITT. Semin. Hematol. 2022;59:72–75. doi: 10.1053/j.seminhematol.2022.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminhematol.2022.02.002</ArticleId><ArticleId IdType="pmc">PMC8820951</ArticleId><ArticleId IdType="pubmed">35512903</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Bissola A.L., Treverton J., Hack M., Lychacz M., Kwok S., Arnold A., Nazy I. Vaccine-Induced Immune Thrombotic Thrombocytopenia: Clinicopathologic Features and New Perspectives on Anti-PF4 Antibody-Mediated Disorders. J. Clin. Med. 2024;13:1012. doi: 10.3390/jcm13041012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm13041012</ArticleId><ArticleId IdType="pmc">PMC10889051</ArticleId><ArticleId IdType="pubmed">38398325</ArticleId></ArticleIdList></Reference><Reference><Citation>Krutzke L., Rösler R., Allmendinger E., Engler T., Wiese S., Kochanek S. Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine. eLife. 2022;11:e78513. doi: 10.7554/eLife.78513.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.78513</ArticleId><ArticleId IdType="pmc">PMC9313527</ArticleId><ArticleId IdType="pubmed">35781137</ArticleId></ArticleIdList></Reference><Reference><Citation>Cines D.B., Bussel J.B. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. N. Engl. J. Med. 2021;384:2254–2256. doi: 10.1056/NEJMe2106315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe2106315</ArticleId><ArticleId IdType="pmc">PMC8063912</ArticleId><ArticleId IdType="pubmed">33861524</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazy I., Sachs U.J., Arnold D.M., McKenzie S.E., Choi P., Althaus K., Ahlen M.T., Sharma R., Grace R.F., Bakchoul T. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. J. Thromb. Haemost. 2021;19:1585–1588. doi: 10.1111/jth.15341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15341</ArticleId><ArticleId IdType="pmc">PMC8250233</ArticleId><ArticleId IdType="pubmed">34018298</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulman S., Arnold D.M., Bradbury C.A., Broxmeyer L., Connors J.M., Falanga A., Iba T., Kaatz S., Levy J.H., Middeldorp S., et al. 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. J. Thromb. Haemost. 2024;22:1779–1797. doi: 10.1016/j.jtha.2024.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtha.2024.02.011</ArticleId><ArticleId IdType="pubmed">38503600</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavord S., Scully M., Hunt B.J., Lester W., Bagot C., Craven B., Rampotas A., Ambler G., Makris M. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N. Engl. J. Med. 2021;385:1680–1689. doi: 10.1056/NEJMoa2109908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109908</ArticleId><ArticleId IdType="pmc">PMC10662971</ArticleId><ArticleId IdType="pubmed">34379914</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini I., Uzun G., Jamal K., Bakchoul T. Treatment of drug-induced immune thrombocytopenias. Haematologica. 2022;107:1264–1277. doi: 10.3324/haematol.2021.279484.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2021.279484</ArticleId><ArticleId IdType="pmc">PMC9152960</ArticleId><ArticleId IdType="pubmed">35642486</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldenburg J., Klamroth R., Langer F., Albisetti M., von Auer C., Ay C., Korte W., Scharf R.E., Pötzsch B., Greinacher A. Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH. Hamostaseologie. 2021;41:184–189.</Citation><ArticleIdList><ArticleId IdType="pubmed">33822348</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A., Toma F., Uzun G., Wagner T.R., Pelzl L., Zlamal J., Freytag V., Weich K., Nowak-Harnau S., Rothbauer U., et al. The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia. Blood. 2022;139:3430–3438. doi: 10.1182/blood.2021013839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021013839</ArticleId><ArticleId IdType="pmc">PMC8949646</ArticleId><ArticleId IdType="pubmed">35679071</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh A., Kelton J.G., Arnold D.M., Daka M., Nazy I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature. 2021;596:565–569. doi: 10.1038/s41586-021-03744-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03744-4</ArticleId><ArticleId IdType="pubmed">34233346</ArticleId></ArticleIdList></Reference><Reference><Citation>James B., Bussel M.J.M.C., Cines D.B., Dunbar C.E., Michaelis L.C., Kreuziger L.B., Lee A.Y.Y., Pabinger-Fasching I. Vaccine-induced Immune Thrombotic Thrombocytopenia 2022 July 10. 2024.  [(accessed on 26 August 2024)].  Available online:  https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia.</Citation></Reference><Reference><Citation>van de Munckhof A., Krzywicka K., Aguiar de Sousa D., Sánchez van Kammen M., Heldner M.R., Jood K., Lindgren E., Tatlisumak T., Putaala J., Kremer Hovinga J.A., et al. Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination. Eur. J. Neurol. 2022;29:339–344. doi: 10.1111/ene.15113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15113</ArticleId><ArticleId IdType="pmc">PMC8652752</ArticleId><ArticleId IdType="pubmed">34536256</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Advice for the Public: Getting Vaccinated. 2022 4/13/2022.  [(accessed on 25 August 2022)].  Available online:  https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice.</Citation></Reference><Reference><Citation>Lopez Bernal J., Andrews N., Gower C., Robertson C., Stowe J., Tessier E., Simmons R., Cottrell S., Roberts R., O’Doherty M., et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. BMJ. 2021;373:n1088. doi: 10.1136/bmj.n1088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1088</ArticleId><ArticleId IdType="pmc">PMC8116636</ArticleId><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin D.R., Higdon M.M., Abu-Raddad L.J., Andrews N., Araos R., Goldberg Y., Groome M.J., Huppert A., O’Brien K.L., Smith P.G., et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression. Lancet. 2022;399:924–944. doi: 10.1016/S0140-6736(22)00152-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00152-0</ArticleId><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf M.E., Luz B., Niehaus L., Bhogal P., Bäzner H., Henkes H. Thrombocytopenia and Intracranial Venous Sinus Thrombosis after “COVID-19 Vaccine AstraZeneca” Exposure. J. Clin. Med. 2021;10:1599. doi: 10.3390/jcm10081599.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10081599</ArticleId><ArticleId IdType="pmc">PMC8069989</ArticleId><ArticleId IdType="pubmed">33918932</ArticleId></ArticleIdList></Reference><Reference><Citation>Uzun G., Althaus K., Hammer S., Wanner Y., Nowak-Harnau S., Enkel S., Bakchoul T. Diagnostic Performance of a Particle Gel Immunoassay in Vaccine-Induced Immune Thrombotic Thrombocytopenia. Hamostaseologie. 2023;43:22–27. doi: 10.1055/a-1986-1556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1986-1556</ArticleId><ArticleId IdType="pubmed">36807823</ArticleId></ArticleIdList></Reference><Reference><Citation>Schönborn L., Seck S.E., Thiele T., Kaderali L., Hoffmann T., Hlinka A., Lindhoff-Last E., Völker U., Selleng K., Buoninfante A., et al. Long-term outcome in vaccine-induced immune thrombocytopenia and thrombosis. J. Thromb. Haemost. 2023;21:2519–2527. doi: 10.1016/j.jtha.2023.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtha.2023.06.027</ArticleId><ArticleId IdType="pubmed">37394120</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy J., Pavord S., Brown K.E. VITT and Second Doses of Covid-19 Vaccine. N. Engl. J. Med. 2022;386:95. doi: 10.1056/NEJMc2118507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2118507</ArticleId><ArticleId IdType="pmc">PMC8757567</ArticleId><ArticleId IdType="pubmed">34936738</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagiota V., Dobbelstein C., Werwitzke S., Ganser A., Cooper N., Sachs U.J., Tiede A. Long-Term Outcomes after Vaccine-Induced Thrombotic Thrombocytopenia. Viruses. 2022;14:1702. doi: 10.3390/v14081702.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14081702</ArticleId><ArticleId IdType="pmc">PMC9415056</ArticleId><ArticleId IdType="pubmed">36016324</ArticleId></ArticleIdList></Reference><Reference><Citation>Arachchillage D.J., Crossette-Thambiah C., Asmar N., Ramji S., Laffan M. Cerebral vein thrombosis after ChAdOx1 nCov-19 vaccination: Long-term outcome of four patients. Res. Pract. Thromb. Haemost. 2022;6:e12844. doi: 10.1002/rth2.12844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12844</ArticleId><ArticleId IdType="pmc">PMC9667410</ArticleId><ArticleId IdType="pubmed">36408296</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindhoff-Last E., Schoenborn L., Piorkowski M., Herold J., Greinacher A., Sheppard J.A., Warkentin T.E. Heterogeneity of Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination and Safety of Second Vaccination with BNT162b2. Thromb. Haemost. 2022;122:304–307. doi: 10.1055/a-1701-2926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1701-2926</ArticleId><ArticleId IdType="pmc">PMC8820842</ArticleId><ArticleId IdType="pubmed">34794199</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotti E., Gori A.M., Berteotti M., Rogolino A., Cesari F., Poli D., Vannini F., Bertelli A., Giusti B., Marcucci R. Natural history of anti-PF 4 antibodies in patients with vaccine-induced immune thrombocytopenia and thrombosis. Blood Transfus. 2024;22:246–252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11073623</ArticleId><ArticleId IdType="pubmed">38315531</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Ismail M.Y., Kanack A.J., Splinter N.P., Smock K.J., Moser K.A., Padmanabhan A. Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT. Blood Adv. 2022;6:5327–5329. doi: 10.1182/bloodadvances.2022007753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2022007753</ArticleId><ArticleId IdType="pmc">PMC9631692</ArticleId><ArticleId IdType="pubmed">35468623</ArticleId></ArticleIdList></Reference><Reference><Citation>Schönborn L., Seck S.E., Thiele T., Warkentin T.E., Greinacher A. SARS-CoV-2 Infection in Patients with a History of VITT. N. Engl. J. Med. 2022;387:88–90. doi: 10.1056/NEJMc2206601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206601</ArticleId><ArticleId IdType="pmc">PMC9258751</ArticleId><ArticleId IdType="pubmed">35759529</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.S.M., Clarke L.J., Kershaw G.W., Tohidi-Esfahani I., Brighton T.A., Chunilal S., Favaloro E.J., Tran H., Chen V.M. Platelet-activating functional assay resolution in vaccine-induced immune thrombotic thrombocytopenia: Differential alignment to PF4 ELISA platforms. Res. Pract. Thromb. Haemost. 2023;7:100128. doi: 10.1016/j.rpth.2023.100128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rpth.2023.100128</ArticleId><ArticleId IdType="pmc">PMC10139939</ArticleId><ArticleId IdType="pubmed">37122532</ArticleId></ArticleIdList></Reference><Reference><Citation>Günther A., Brämer D., Pletz M.W., Kamradt T., Baumgart S., Mayer T.E., Baier M., Autsch A., Mawrin C., Schönborn L., et al. Complicated Long Term Vaccine Induced Thrombotic Immune Thrombocytopenia-A Case Report. Vaccines. 2021;9:1344. doi: 10.3390/vaccines9111344.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9111344</ArticleId><ArticleId IdType="pmc">PMC8622649</ArticleId><ArticleId IdType="pubmed">34835275</ArticleId></ArticleIdList></Reference><Reference><Citation>Montague S.J., Smith C.W., Lodwick C.S., Stoneley C., Roberts M., Lowe G.C., Lester W.A., Watson S.P., Nicolson P.L.R. Anti-platelet factor 4 immunoglobulin G levels in vaccine-induced immune thrombocytopenia and thrombosis: Persistent positivity through 7 months. Res. Pract. Thromb. Haemost. 2022;6:e12707. doi: 10.1002/rth2.12707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12707</ArticleId><ArticleId IdType="pmc">PMC9066380</ArticleId><ArticleId IdType="pubmed">35515079</ArticleId></ArticleIdList></Reference><Reference><Citation>Craven B., Lester W., Boyce S., Thomas W., Kanny A., Davies C., Pavord S., Hermans J., Makris M., Bart-Smith E. Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis. Blood. 2022;139:2553–2560. doi: 10.1182/blood.2021014684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021014684</ArticleId><ArticleId IdType="pmc">PMC8912978</ArticleId><ArticleId IdType="pubmed">35263420</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>